Search Results - "Brose, M."

Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma by Schlumberger, M., Elisei, R., Müller, S., Schöffski, P., Brose, M., Shah, M., Licitra, L., Krajewska, J., Kreissl, M.C., Niederle, B., Cohen, E.E.W., Wirth, L., Ali, H., Clary, D.O., Yaron, Y., Mangeshkar, M., Ball, D., Nelkin, B., Sherman, S.

“…Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant…”
Get full text

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study by Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

“…NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive…”
Get full text

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial by Smallridge, R. C, Copland, J. A, Brose, M. S, Wadsworth, J. T, Houvras, Y, Menefee, M. E, Bible, K. C, Shah, M. H, Gramza, A. W, Klopper, J. P, Marlow, L. A, Heckman, M. G, Von Roemeling, R

“…Purpose: A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose and recommended phase 2 dose of efatutazone…”
Get full text

Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus by Wouters, E. F. M, Bredenbröker, D, Teichmann, P, Brose, M, Rabe, K. F, Fabbri, L. M, Göke, B

“…Context: The phosphodiesterase 4 inhibitor roflumilast is a first-in-class antiinflammatory treatment for severe chronic obstructive pulmonary disease (COPD)…”
Get full text

Targeted Inhibition of CD133+ Cells in Oral Cancer Cell Lines by Damek-Poprawa, M., Volgina, A., Korostoff, J., Sollecito, T.P., Brose, M.S., O’Malley, B.W., Akintoye, S.O., DiRienzo, J.M.

“…Resistance to treatment and the appearance of secondary tumors in head and neck squamous cell carcinomas (HNSCC) have been attributed to the presence of cells…”
Get full text

Absence of BRAF mutations in UV-protected mucosal melanomas by Edwards, R H, Ward, M R, Wu, H, Medina, C A, Brose, M S, Volpe, P, Nussen-Lee, S, Haupt, H M, Martin, A M, Herlyn, M, Lessin, S R, Weber, B L

“…Background: Mutations in BRAF have recently been identified in a significant percentage of primary and metastatic cutaneous malignant melanomas. As ultraviolet…”
Get full text

Preliminary results from a phase II trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations by Ho, A.L., Chau, N., Bauman, J., Bible, K., Chintakuntlawar, A., Cabanillas, M.E., Wong, D.J., Braña Garcia, I., Brose, M.S., Boni, V., Even, C., Razaq, M., Mishra, V., Bracken, K., Wages, D., Scholz, C., Gualberto, A.

Get full text

Renal scintigraphy as an early and efficient method for detecting loss of renal function in a cat by Schaefer, Gabriela C, Brose, Mariana M, Becerra, José R Herrera, Mello, Fabíola PS, Rovaris, Inácio B, Herz Berdichevski, Eduardo, Ferreira, Márcio P, da Costa, Fernanda VA

“…Case summary A 6-year-old mixed-breed male cat was evaluated for a routine annual health assessment. No alterations on physical examination were observed other…”
Get full text

Distinct C4 sub‐types and C3 bundle sheath isolation in the Paniceae grasses by Washburn, Jacob D., Strable, Josh, Dickinson, Patrick, Kothapalli, Satya S., Brose, Julia M., Covshoff, Sarah, Conant, Gavin C., Hibberd, Julian M., Pires, Joseph Chris

“…In C4 plants, the enzymatic machinery underpinning photosynthesis can vary, with, for example, three distinct C4 acid decarboxylases being used to release CO2…”
Get full text

The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK by Neely, R J, Brose, M S, Gray, C M, McCorkell, K A, Leibowitz, J M, Ma, C, Rothstein, J L, May, M J

“…The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates…”
Get full text

The RET/PTC3 oncogene activates classical NF-[kappa]B by stabilizing NIK by Neely, R J, Brose, M S, Gray, C M, Mccorkell, K A, Leibowitz, J M, Ma, C, Rothstein, J L, May, M J

“…The oncogenic fusion protein RET/PTC3 (RP3) that is expressed in papillary thyroid carcinoma (PTC) and thyroid epithelia in Hashimoto's thyroiditis activates…”
Get full text

The intentional pursuit of everyday life while dying: A longitudinal qualitative study of working-aged adults living with advanced cancer by Brose, Julie M, Willis, Eileen, Morgan, Deidre D

“…Background: People living with advanced cancer experience functional decline and increasing difficulty participating in activities of daily living over their…”
Get full text

Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program by Brose, Marcia S., Rebbeck, Timothy R., Calzone, Kathleen A., Stopfer, Jill E., Nathanson, Katherine L., Weber, Barbara L.

“…Background: Increasing numbers of BRCA1 mutation carriers are being identified in cancer risk evaluation programs. However, no estimates of cancer risk…”
Get full text

The Essential Role of Occupational Therapy to Address Functional Needs of Individuals Living with Advanced Chronic Cancers by Dolgoy, Naomi, Driga, Amy, Brose, Julie M.

“…Medical progress in cancer care has led to increased life expectancy outcomes across all stages of cancer, including in advanced cancers. People now living…”
Get full text

Occupational adaptation for adults living with advanced cancer: A phenomenological longitudinal study by Brose, Julie M., Willis, Eileen, Morgan, Deidre D.

“…Introduction People living with advanced cancer want to continue participating in their valued occupations amid cancer progression. However, increasing…”
Get full text

A comparative study of EGFR mutation screening methods in non-small cell carcinoma of lung by Gombos, Z, Danihel, L, Puttaswamy, K, Brose, M

“…Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase of the ERBB2 family that has important roles in the proliferation and…”
Get more information

Phylogeny and multiple independent whole‐genome duplication events in the Brassicales by Mabry, Makenzie E., Brose, Julia M., Blischak, Paul D., Sutherland, Brittany, Dismukes, Wade T., Bottoms, Christopher A., Edger, Patrick P., Washburn, Jacob D., An, Hong, Hall, Jocelyn C., McKain, Michael R., Al‐Shehbaz, Ihsan, Barker, Michael S., Schranz, M. Eric, Conant, Gavin C., Pires, J. Chris

“…Premise Whole‐genome duplications (WGDs) are prevalent throughout the evolutionary history of plants. For example, dozens of WGDs have been phylogenetically…”
Get full text

Effect of age on the efficacy and safety of lenvatinib for the treatment of 131i-refractory differentiated thyroid cancer in the phase 3 select study by Brose, M, Schlumberger, M, Tahara, M, Wirth, L.J, Robinson, B, Elisei, R, Newbold, K, Kiyota, N, Hoff, A.O, Dutcus, C.E, Heras, B.D.L, Zhu, J, Sherman, S.I, Taylor, M

Get full text

Germline CHEK21100delC mutations in breast cancer patients with multiple primary cancers by Huang, J, Domchek, S M, Brose, M S, Rebbeck, T R, Nathanson, K L, Weber, B L

Get full text

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial by Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M., Hurria, A.

Get full text